Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2716 USD | -3.76% | -10.33% | -87.19% |
May. 14 | Transcript : ENDRA Life Sciences Inc., Q1 2024 Earnings Call, May 14, 2024 | |
May. 14 | Endra Life Sciences Inc. Announces Impairment Charges for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | 200K | Sales 2025 * | 1M | Capitalization | 3.11M |
---|---|---|---|---|---|
Net income 2024 * | -11M | Net income 2025 * | -12M | EV / Sales 2024 * | 15.6 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3.11 x |
P/E ratio 2024 * |
-0.27
x | P/E ratio 2025 * |
-0.27
x | Employees | 21 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.85% |
Latest transcript on ENDRA Life Sciences Inc.
1 day | -3.76% | ||
1 week | -10.33% | ||
Current month | -3.99% | ||
1 month | +1.57% | ||
3 months | -75.75% | ||
6 months | -72.57% | ||
Current year | -87.19% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 14-12-31 | |
Irina Pestrikova
DFI | Director of Finance/CFO | 38 | 21-06-17 |
Michael Thornton
CTO | Chief Tech/Sci/R&D Officer | 55 | 06-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 13-06-30 | |
Alexander Tokman
BRD | Director/Board Member | 62 | 07-12-31 |
Michael Harsh
BRD | Director/Board Member | 69 | 14-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 0.2716 | -3.76% | 37 434 |
24-05-24 | 0.2822 | +0.39% | 52,595 |
24-05-23 | 0.2811 | -10.88% | 116,632 |
24-05-22 | 0.3154 | +4.13% | 166,113 |
24-05-21 | 0.3029 | -5.34% | 111,406 |
Delayed Quote Nasdaq, May 28, 2024 at 01:04 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-87.19% | 3.11M | |
+51.16% | 63.85B | |
-2.33% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.40% | 26.52B | |
-21.55% | 18.69B | |
+2.68% | 12.73B | |
+21.49% | 12.11B | |
+28.01% | 12.07B |
- Stock Market
- Equities
- NDRA Stock